Zymeworks Current Ratio 2016-2021 | ZYME

Zymeworks current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zymeworks Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.39B $0.08B 4.73
2021-03-31 $0.43B $0.07B 6.16
2020-12-31 $0.46B $0.09B 5.31
2020-09-30 $0.49B $0.10B 5.03
2020-06-30 $0.47B $0.07B 6.48
2020-03-31 $0.51B $0.07B 6.92
2019-12-31 $0.31B $0.08B 3.78
2019-09-30 $0.35B $0.05B 6.81
2019-06-30 $0.37B $0.04B 9.07
2019-03-31 $0.19B $0.03B 6.76
2018-12-31 $0.20B $0.03B 6.82
2018-09-30 $0.15B $0.02B 6.42
2018-06-30 $0.17B $0.02B 7.26
2018-03-31 $0.07B $0.02B 4.09
2017-12-31 $0.09B $0.02B 6.30
2017-09-30 $0.05B $0.01B 4.57
2017-06-30 $0.07B $0.01B 5.60
2017-03-31 $0.03B $0.02B 1.57
2016-12-31 $0.05B $0.02B 2.81
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.02B $0.01B 3.64
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.088B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57